A 20-year-old cancer vaccine may hold the key to long-term survival

Two decades after a breast cancer vaccine trial, every participant is still alive—an astonishing result for metastatic disease. Scientists found their immune systems retained long-lasting memory cells primed to recognize cancer. By enhancing a key immune signal called CD27, researchers dramatically improved tumor elimination in lab studies. The findings suggest cancer vaccines may have been missing a crucial ingredient all along.

Health Jan 30, 2026 0 6 Add to Reading List

A 20-year-old cancer vaccine may hold the key to long-term survival

WHY THE HEN DOES NOT HAVE TEETH STORY BOOK

It’s an amazing story, composed out of imagination and rich with lessons. You’ll learn how to be morally upright, avoid immoral things, and understand how words can make or destroy peace and harmony.

Click the image to get your copy!

WHY THE HEN DOES NOT HAVE TEETH STORY BOOK

Click the image to get your copy!

WHY THE HEN DOES NOT HAVE TEETH STORY BOOK

Click the image to get your copy!

Two decades after a breast cancer vaccine trial, every participant is still alive—an astonishing result for metastatic disease. Scientists found their immune systems retained long-lasting memory cells primed to recognize cancer. By enhancing a key immune signal called CD27, researchers dramatically improved tumor elimination in lab studies. The findings suggest cancer vaccines may have been missing a crucial ingredient all along.

Read Original